# A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

> **NCT00140140** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 16 (actual)

## Conditions studied

- Stage IV (Metastatic) Breast Cancer

## Interventions

- **DRUG:** ABI-007
- **DRUG:** vinorelbine
- **DRUG:** Trastuzumab
- **BIOLOGICAL:** G-CSF

## Key facts

- **NCT ID:** NCT00140140
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Unable to determine the optimum tolerated dose
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140140, "A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00140140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*